Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1097/MCC.0000000000000860 http://scihub22266oqcxt.onion/10.1097/MCC.0000000000000860 34321415!8452245!34321415     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Curr+Opin+Crit+Care 2021 ; 27 (5): 468-473 Nephropedia Template TP {{tp|p=34321415|t=2021. Secondary pneumonias in critically ill patients with COVID-19: risk factors and outcomes |pdf=|usr=}}{{34321415}} gab.com Text Secondary pneumonias in critically ill patients with COVID-19: risk factors and outcomes JO: Curr Opin Crit Care http://www.kidney.de/pget.php?&tw=1&pmid=34321415 #FOAvip PURPOSE OF REVIEW: The aim of this review is to provide an overview of the current evidence of secondary pneumonias in COVID-19 patients, its incidence, risk factors and impact outcomes. RECENT FINDINGS: Early studies reported low incidence of hospital-acquired infections in COVID-19 patients. More recent large studies clearly showed that the incidence of secondary pneumonias was markedly high in patients under mechanical ventilation. Duration of mechanical ventilation, acute respiratory distress syndrome, prone position and male sex were identified as risk factors. The adjunctive therapy with steroids and immunomodulators were associated with a higher risk of pneumonia and invasive pulmonary Aspergillosis. Although secondary pneumonias seemed to be associated with poor outcomes, namely mortality, in comparison with influenza, no difference was found in heterogeneity of outcomes. Immunosuppressive therapy has been studied in several observational and randomized trials with conflicting results and the true impact on superinfections, namely secondary pneumonias, has not been properly assessed. SUMMARY: According to the current evidence, COVID-19 patients are at an increased risk of secondary pneumonias. The impact of immunosuppressive therapies on superinfections is yet to be determined. Further studies are needed to assess the true risk of secondary infections associated with immunosuppressive therapies and to identify preventive strategies. Twit Text FOAVip Secondary pneumonias in critically ill patients with COVID-19: risk factors and outcomes ????Curr Opin Crit Care http://www.kidney.de/pget.php?&tw=1&pmid=34321415 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34321415 #FOAvip English Wikipedia <ref>{{Cite pmid|34321415}}</ref> Secondary pneumonias in critically ill patients with COVID-19: risk factors and outcomes #MMPMID34321415 Povoa P; Martin-Loeches I; Nseir S Curr Opin Crit Care 2021[Oct]; 27 (5): 468-473 PMID34321415show ga PURPOSE OF REVIEW: The aim of this review is to provide an overview of the current evidence of secondary pneumonias in COVID-19 patients, its incidence, risk factors and impact outcomes. RECENT FINDINGS: Early studies reported low incidence of hospital-acquired infections in COVID-19 patients. More recent large studies clearly showed that the incidence of secondary pneumonias was markedly high in patients under mechanical ventilation. Duration of mechanical ventilation, acute respiratory distress syndrome, prone position and male sex were identified as risk factors. The adjunctive therapy with steroids and immunomodulators were associated with a higher risk of pneumonia and invasive pulmonary Aspergillosis. Although secondary pneumonias seemed to be associated with poor outcomes, namely mortality, in comparison with influenza, no difference was found in heterogeneity of outcomes. Immunosuppressive therapy has been studied in several observational and randomized trials with conflicting results and the true impact on superinfections, namely secondary pneumonias, has not been properly assessed. SUMMARY: According to the current evidence, COVID-19 patients are at an increased risk of secondary pneumonias. The impact of immunosuppressive therapies on superinfections is yet to be determined. Further studies are needed to assess the true risk of secondary infections associated with immunosuppressive therapies and to identify preventive strategies. |*COVID-19[MESH] |*Pneumonia/epidemiology/etiology[MESH] |Critical Illness[MESH] |Humans[MESH] |Male[MESH] |Respiration, Artificial/adverse effects[MESH] |Risk Factors[MESH]Secondary pneumonias in critically ill patients with COVID-19: risk fa(epmc).pdf DeepDyve Pubget Overpricing